Answers are grounded in this paper and cite their sources.
Xerostomia is a frequent adverse effect of ¹⁷⁷Lu-PSMA and the dose-limiting toxicity of ²²⁵Ac-PSMA radioligand therapy (RLT). Many empirical protective measures are used, but they have not been systematically appraised across both imaging-surrogate and clinical studies, or across beta- and alpha-emitters.
No takes yet. Share an insight, caveat, or question.
Stefan Adrian Vöö (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: